Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Die nächste Sicherheitsgeneration: Quantenresistente Technologie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
BP

WKN: A42KRT | ISIN: US59564R8640 | Ticker: 5MP3
Frankfurt
16.11.26 | 21:43
1,510 Euro
-8,48 % -0,140
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIODEXA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
BIODEXA PHARMACEUTICALS PLC ADR 5-Tage-Chart

Aktuelle News zur BIODEXA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
09.11.Biodexa reports progress on FAP and GIST drug trials1
09.11.Biodexa Pharmaceuticals PLC: Biodexa provides R&D Update1
09.11.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer-
28.10.XFRA NEW INSTRUMENTS AVAILABLE ON 28.10.2026521The following instruments on XETRA do have their first trading 28.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.10.2026 Aktien 1 US59564R8640 Biodexa Pharmaceuticals...
► Artikel lesen
13.10.Biodexa schließt 100 Patienten in Phase-3-Studie Serenta bei FAP ein4
08.10.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
BIODEXA PHARMACEUTICALS Aktie jetzt für 0€ handeln
02.10.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4-2.858The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO...
► Artikel lesen
24.09.Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers-
23.09.Biodexa Pharmaceuticals PLC: The Longview: Fireside Chat with Biodexa CEO Stephen Stamp582Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower...
► Artikel lesen
15.09.Biodexa Pharmaceuticals enters warrant exercise transaction for $2.3M gross proceeds; shares rise3
11.09.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer6
11.09.Biodexa Pharmaceuticals PLC: Interim results for the six months ended June 30, 2026654September 11, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
► Artikel lesen
11.09.Biodexa Pharmaceuticals reports 1H results5
19.08.Biodexa passes halfway mark in Phase 3 trial recruitment for FAP3
19.08.Biodexa Pharmaceuticals PLC: Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP776August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa"...
► Artikel lesen
30.07.Biodexa Pharmaceuticals Plc - F-1/A, Registration statement for certain foreign private issuers1
29.07.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer3
29.07.Biodexa Pharmaceuticals PLC: Result of General Meeting431July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative...
► Artikel lesen
15.07.Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers2
09.07.Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer1
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1